Sri N. Prakasa Rao is an Educationist (30 Years Experience in Education Field) and a man with a vision & mission of providing Quality Education from K.G. to P.G, affordable to the People in and around Prakasam District From Last two Decades.
Our goal is to help you successfully reach your academic and professional aspirations and equip you with the skills you need to make a difference in your workplace and in your community.
Education is the basis of all progress. It is for this very reason that we forayed into education, about 30 years ago. Over a decade and a half of experience has taught us that progress is possible only, if men and women are equally well-educated..
The entire purpose of education is not to restrict itself to imparting bookish knowledge only but inculcate humanitarian values like wisdom, compassion, courage, humility, integrity and reliability in a student.
We, just like you, believe in holistic education for your child, encompassing – academics, co-curricular activities, sports education and life-skills learning. Our endeavor is to strike a balance between state-of-the-art infrastructure and an internationally acceptable education.
> At Vidya, we impart education that is based on conscience and we rear a breed of young minds that are bustling with self confidence, motivation and ever ready to take up challenges.
> The campus, sports and academic facilities all bear testimony to this effort. In order to promote an internationally acceptable education, our key focus has been on faculty development – providing continuous teacher training in order to deliver real value education and excellence in academics. Teachers are trained not only to teach well but are also expected to inspire confidence and trust in their students and become role models. Further, the School inculcates in the students a respect for tradition and ensures discipline and good manners.
> Vidya Institutions encourages students to learn about themselves and their constantly changing environment, while at the same time offering support and guidance as they practise decision-making and social skills.
> We are confident that this school is the best place for your child. We welcome your active interest and involvement in the progress and activities of your child. We look forward to your continuous support.
Vidya Organizes 4 Colleges, 4 Schools and 1 Study Center
Sri N. Prakasa Rao is an Educationist (30 Years Experience in Education Field) and a man with a vision on a mission of providing Quality Education from K.G. to P.G, affordable to the People in and around Prakasam District From Last two Decades.
Dr. Mehta brings over two decades of experience in successfully designing and implementing innovative solutions, establishing global commercial operations, leading cross-functional teams and building strong intercontinental client bases. During the length of his career, he has garnered a deep understanding of the biopharma and healthcare ecosystem and has been actively involved in diverse global value generating initiatives encompassing corporate strategy and planning, global business development, and corporate fundraising. He has been instrumental in helping architect the company’s strategic and business trajectory and has been a visionary thinker throughout his career.
Mr. Kydonieus is President and Chief Business Officer of R-Pharm U.S. located in Princeton NJ, where he is accelerating the growth and commercial infrastructure through acquisition and licensing of specialty products for Russia’s leading pharmaceutical company R-Pharm CJSC. Prior to starting R-Pharm US he worked at Bristol Myers Squibb for the prior 15 years where he most recently served as Vice President of Strategy, Alliances and Transactions. Mr. Kydonieus is a highly experienced and successful pharmaceutical executive with broad experience in Business Development, Legal, Regulatory and Compliance.
Dr. Nandabalan brings over two decades of experience across multiple functions in the pharmaceutical and biotechnology industries, including research & development, operations, and business development. He has extensive experience in M&A and in/out-licensing. He has 12 issued patents and has published in leading journals such as Cell and Science. Dr. Nandabalan has garnered a deep understanding of market trends impacting the global healthcare environment, the pharma value chain, the current unmet medical needs, and in applying novel technologies to solve these needs.
Dr. Laumas is the founder and Chief Executive Officer of Bearing Circle Capital in Greenwich, Connecticut. He started his career at Goldman Sachs & Co. in New York in the Investment Banking Division. Dr. Laumas then joined Balyasny Asset Management in New York and later moved to North Sound Capital in Greenwich, Connecticut as a Managing Director responsible for global healthcare investments. Dr. Laumas has served as a director of SRL Diagnostics Ltd., Asia’s largest clinical laboratory services company and as a director of Parkway Holdings Ltd. (IHH Healthcare: Singapore: IHH), Asia’s largest hospital company and Innovate Biopharmaceuticals, Inc. Dr. Laumas has a unique industry perspective, particularly in both public and private investments and financial transactions in the healthcare arena.
Dr. Nandabalan brings over two decades of experience across multiple functions in the pharmaceutical and biotechnology industries, including research & development, operations, and business development. He has extensive experience in M&A and in/out-licensing. He has 12 issued patents and has published in leading journals such as Cell and Science. Dr. Nandabalan has garnered a deep understanding of market trends impacting the global healthcare environment, the pharma value chain, the current unmet medical needs, and in applying novel technologies to solve these needs.
Dr. Frank Yocca is a pharma R&D executive and scientist with extensive experience leading global biopharmaceutical companies. He has a wide ranging expertise in leading and working in high performance world-class teams in drug discovery and development that has led to the discovery, development and licensing of prominent neuroscience products including Buspar®, Serzone®Abilify® and Heltioz®. He is a recognized scientific leader in the Neuroscience community and member of the Institute of Medicine of the National Academy of Science, and a Fellow of American College of Neuropsychopharmacology. He has 45 referred articles, 96 abstracts and 65 invited presentations.
Dr. Luca Rastelli has more than 20 years of drug discovery and development experience in pharmaceutical, biotech and start-up companies. He discovered the target and led the initial development of CR011, an antibody drug conjugate agent undergoing a registrational trial in triple negative metastatic breast cancer. He has significant experience in identifying, evaluating and acquiring external innovation opportunities through collaborative and in-licensing efforts. He received the American Brain Tumor Association’s 25th Anniversary Translational grant for his work on Medulloblastoma tumors at the Department of Neuro-Oncology, MD Anderson Cancer Center.
Mr.Mahadevan is responsible for leading the finance and accounting functions of the company and has extensive experience and knowledge of finance management in the software and pharmaceutical industries.
Mr. Sethi has more than a decade of experience, in business management, operations, sales and marketing and has extensive knowledge in growing value driven business operations, including resource planning, and client relationship management.
Mr. Kant is a seasoned business development executive with over a decade of experience in establishing strategy, commercial excellence and operations. He has extensive knowledge in building and leading sales & marketing teams to consummate numerous successful deals. He is highly focused and adept at delivering value to partners through technology solutions with a depth of knowledge across Big Data and Artificial Intelligence to impact the biopharma innovation.
Dr. Peter Mueller is the President of R&D and Chief Scientific Officer at Axcella Health. Prior to joining Axcella, Dr. Mueller served as the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals where he provided strategic oversight for Vertex’s worldwide drug discovery and development programs. Under his leadership, the company secured approval for and launched two breakthrough drugs, INCIVEK® (HepC) in 2011, and KALYDECO® (CF) in 2012. Additionally, Vertex submitted both an NDA and MAA for ORKAMBI® (CF). Prior to his time at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc., where he played a key role in the development of Spiriva®, Combivent®, and Atrovent®. He is a member of various scientific and political societies, including the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (U.K.), IRI, RNA-Society, ASAP, AAAS (U.S.A.) and currently serves on several Boards and Scientific Advisory Board in companies and organizations including US-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, University Iowa (CBB), Keystone Symposia, Inhibikase Therapeutics, Inc., and Kaleido Biosciences, Inc. Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.